Figg WD - Search Results

1

CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. Beverage JN, et al. Among authors: figg wd. J Pharm Sci. 2007 Sep;96(9):2224-31. doi: 10.1002/jps.20892. J Pharm Sci. 2007. PMID: 17518364 Review.

2

Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells.

Danesi R, Figg WD, Reed E, Myers CE. Danesi R, et al. Among authors: figg wd. Mol Pharmacol. 1995 Jun;47(6):1106-11. Mol Pharmacol. 1995. PMID: 7603448

3

Pharmacokinetics of thalidomide in an elderly prostate cancer population.

Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E. Figg WD, et al. J Pharm Sci. 1999 Jan;88(1):121-5. doi: 10.1021/js980172i. J Pharm Sci. 1999. PMID: 9874712 Clinical Trial.

4

A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV. Bergan RC, et al. Among authors: figg wd. Clin Cancer Res. 1999 Sep;5(9):2366-73. Clin Cancer Res. 1999. PMID: 10499606 Clinical Trial.

5

Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Sparreboom A, et al. Among authors: figg wd. Drug Resist Updat. 2003 Apr;6(2):71-84. doi: 10.1016/s1368-7646(03)00005-0. Drug Resist Updat. 2003. PMID: 12729805 Review.

6

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. Paoluzzi L, et al. Among authors: figg wd. J Clin Pharmacol. 2004 Aug;44(8):854-60. doi: 10.1177/0091270004267159. J Clin Pharmacol. 2004. PMID: 15286088

7

Effect of ABCG2 genotype on the oral bioavailability of topotecan.

Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H. Sparreboom A, et al. Among authors: figg wd. Cancer Biol Ther. 2005 Jun;4(6):650-8. doi: 10.4161/cbt.4.6.1731. Epub 2005 Jun 11. Cancer Biol Ther. 2005. PMID: 15908806

8

Modulation of cytochrome P450 activity: implications for cancer therapy.

Scripture CD, Sparreboom A, Figg WD. Scripture CD, et al. Among authors: figg wd. Lancet Oncol. 2005 Oct;6(10):780-9. doi: 10.1016/S1470-2045(05)70388-0. Lancet Oncol. 2005. PMID: 16198984 Review.

9

Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.

Sissung TM, Price DK, Sparreboom A, Figg WD. Sissung TM, et al. Among authors: figg wd. Mol Cancer Res. 2006 Mar;4(3):135-50. doi: 10.1158/1541-7786.MCR-05-0101. Mol Cancer Res. 2006. PMID: 16547151 Review.

10

Drug interactions in cancer therapy.

Scripture CD, Figg WD. Scripture CD, et al. Among authors: figg wd. Nat Rev Cancer. 2006 Jul;6(7):546-58. doi: 10.1038/nrc1887. Nat Rev Cancer. 2006. PMID: 16794637 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

774 results

Search Page